BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology
BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease.
